이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Organogenesis Holdings 관리

관리 기준 확인 3/4

Organogenesis Holdings' CEO는 Gary Gillheeney, Jan2014 에 임명되었습니다 의 임기는 10.42 년입니다. 총 연간 보상은 $ 6.24M, 14.6% 로 구성됩니다. 14.6% 급여 및 85.4% 보너스(회사 주식 및 옵션 포함). 는 € 1.93M 가치에 해당하는 회사 주식의 0.63% 직접 소유합니다. 1.93M. 경영진과 이사회의 평균 재임 기간은 각각 6.8 년과 3.6 년입니다.

주요 정보

Gary Gillheeney

최고 경영자

US$6.2m

총 보상

CEO 급여 비율	14.6%
CEO 임기	10.4yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	6.8yrs
이사회 평균 재임 기간	3.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Gary Gillheeney 의 보수는 Organogenesis Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$6m
Dec 31 2023	US$6m	US$909k	US$5m
Sep 30 2023	n/a	n/a	US$13m
Jun 30 2023	n/a	n/a	US$10m
Mar 31 2023	n/a	n/a	US$13m
Dec 31 2022	US$6m	US$883k	US$16m
Sep 30 2022	n/a	n/a	US$59m
Jun 30 2022	n/a	n/a	US$71m
Mar 31 2022	n/a	n/a	US$83m
Dec 31 2021	US$4m	US$835k	US$94m
Sep 30 2021	n/a	n/a	US$62m
Jun 30 2021	n/a	n/a	US$69m
Mar 31 2021	n/a	n/a	US$43m
Dec 31 2020	US$3m	US$823k	US$17m
Sep 30 2020	n/a	n/a	-US$5m
Jun 30 2020	n/a	n/a	-US$37m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$1m	US$819k	-US$39m
Sep 30 2019	n/a	n/a	-US$46m
Jun 30 2019	n/a	n/a	-US$48m
Mar 31 2019	n/a	n/a	-US$58m
Dec 31 2018	US$3m	US$798k	-US$65m
Sep 30 2018	n/a	n/a	-US$60m
Jun 30 2018	n/a	n/a	-US$52m
Mar 31 2018	n/a	n/a	-US$32m
Dec 31 2017	US$1m	US$780k	-US$9m

보상 대 시장: Gary 의 총 보상 ($USD 6.24M )은 German 시장( $USD 1.06M ).

보상과 수익: Gary 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Gary Gillheeney (69 yo)

10.4yrs

테뉴어

US$6,244,671

보상

Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018 & serves as its Chair of the Board...

리더십 팀

이름	위치	테뉴어	보상	소유권
Gary Gillheeney	President	10.4yrs	US$6.24m	0.63% $ 2.2m
David Francisco	Chief Financial Officer	3.3yrs	US$1.63m	0.048% $ 166.9k
Patrick Bilbo	Chief Operating Officer	6.8yrs	US$2.16m	0.26% $ 907.1k
Lori Freedman	Chief Administrative & Legal Officer	7.4yrs	US$1.99m	0.063% $ 219.3k
Brian Grow	Chief Commercial Officer	6.8yrs	US$1.92m	0.078% $ 271.4k
William Kolb	Secretary	no data	데이터 없음	데이터 없음
Robert Cavorsi	Vice President of Strategy	3.4yrs	데이터 없음	데이터 없음

6.8yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 관리: 2PQ 의 관리팀은 노련하고 경험 (평균 재직 기간 6.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gary Gillheeney	President	5.5yrs	US$6.24m	0.63% $ 2.2m
Glenn Nussdorf	Director	21.4yrs	데이터 없음	11.29% $ 39.1m
Alan Ades	Director	21.4yrs	데이터 없음	11.5% $ 39.8m
Arthur Leibowitz	Lead Independent Director	5.5yrs	US$291.46k	0.10% $ 357.0k
Robert Ades	Director	3.6yrs	데이터 없음	데이터 없음
Jon Giacomin	Independent Director	3.1yrs	US$265.00k	0.068% $ 234.8k
Michele Korfin	Independent Director	2.1yrs	US$226.98k	0.068% $ 234.3k
Prathyusha Duraibabu	Independent Director	2.6yrs	US$240.00k	0.071% $ 245.3k
David Erani	Director	3.6yrs	데이터 없음	데이터 없음
Michael Driscoll	Independent Director	2.3yrs	US$230.52k	데이터 없음
Gilberto Quintero	Independent Director	2.1yrs	US$226.98k	0.068% $ 234.3k

3.6yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: 2PQ 의 이사회는 경험(평균 재직 기간 3.6 년)으로 간주됩니다.

Organogenesis Holdings 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Organogenesis Holdings Inc., Annual General Meeting, Jun 20, 2024

Insider recently sold €70k worth of stock

High number of new directors

Insider recently sold €94k worth of stock

High number of new directors

Insider recently sold €860k worth of stock

Recent updates

Investor sentiment improves as stock rises 28%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

First quarter 2024 earnings released: US$0.016 loss per share (vs US$0.023 loss in 1Q 2023)

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Organogenesis Holdings Inc., Annual General Meeting, Jun 20, 2024

Organogenesis Holdings Inc. to Report Q1, 2024 Results on May 09, 2024

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Investor sentiment deteriorates as stock falls 18%

New minor risk - Earnings quality

Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024

Full year 2023 earnings released: EPS: US$0.038 (vs US$0.12 in FY 2022)

Organogenesis Holdings Inc. to Report Q4, 2023 Results on Feb 29, 2024

Insider recently sold €70k worth of stock

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 17%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings released: EPS: US$0.024 (vs US$0.002 in 3Q 2022)

High number of new directors

Organogenesis Holdings Inc. to Report Q3, 2023 Results on Nov 09, 2023

Organogenesis Holdings Inc. Withdraws Earnings Guidance for the the 2023

Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.067 in 2Q 2022)

Investor sentiment deteriorates as stock falls 19%

Investor sentiment improves as stock rises 23%

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 47%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.023 loss per share (vs US$0.001 profit in 1Q 2022)

Insider recently sold €94k worth of stock

Investor sentiment deteriorates as stock falls 21%

Full year 2022 earnings released: EPS: US$0.12 (vs US$0.73 in FY 2021)

Investor sentiment deteriorates as stock falls 18%

Organogenesis Holdings Inc. to Report Q4, 2022 Results on Mar 01, 2023

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.002 (vs US$0.098 in 3Q 2021)

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Organogenesis Holdings Inc. to Report Q3, 2022 Results on Nov 09, 2022

Investor sentiment deteriorated over the past week

Organogenesis Receives FDA Clearance for Next Generation PuraPly Surgical Solution

Second quarter 2022 earnings released: EPS: US$0.067 (vs US$0.16 in 2Q 2021)

Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Organogenesis Holdings Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insider recently sold €860k worth of stock

Insider recently bought €58k worth of stock

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

First quarter 2022 earnings released: EPS: US$0.001 (vs US$0.078 in 1Q 2021)

Organogenesis Holdings Inc. Announces Board Changes

High number of new directors

Organogenesis Holdings Inc., Annual General Meeting, Jun 23, 2022

Organogenesis Holdings Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Now 21% undervalued after recent price drop

Organogenesis Appoints Michael J. Driscoll to Board of Directors

Organogenesis Holdings Inc. to Report Q4, 2021 Results on Mar 01, 2022

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Organogenesis Holdings Inc. Investors

Pomerantz LLP Files Class Action Lawsuit Against Organogenesis Holdings Inc

Director recently bought €219k worth of stock

Third quarter 2021 earnings released: EPS US$0.098 (vs US$0.20 in 3Q 2020)

Insider recently bought €139k worth of stock

Investor sentiment deteriorated over the past week

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending Ended December 31, 2021

Second quarter 2021 earnings released: EPS US$0.16 (vs US$0.049 loss in 2Q 2020)

Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 3000E Index